CD263 (TRAIL-R3) Antibody, anti-human, PE 130-124-882 from Miltenyi Biotec | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
Miltenyi Biotec for
CD263 (TRAIL-R3) Antibody, anti-human, PE

The CD263 (TRAIL-R3) Antibody, anti-human, PE from Miltenyi Biotec is a Mouse Monoclonal antibody to TNFRSF10C. This antibody recognizes Human antigen. The CD263 (TRAIL-R3) Antibody, anti-human, PE has been validated for the following applications: Flow Cytometry.

Product Specs
ItemCD263 (TRAIL-R3) Antibody, anti-human, PE
CompanyMiltenyi Biotec
Price Pricing Info Supplier Page View Company Product Page
Catalog Number130-124-882
Quantity100 tests in 200 µL
ApplicationsFlow cytometry
Concentration1:50
Conjugate/TagPE
FormatReagents are supplied in buffer containing stabilizer and 0.05% sodium azide
Reactivityhuman
TargetCD263 (TRAIL-R3)
IsotypeIgG1
CloneDJR3
Hostmouse
Antibody TypePrimary antibodies
NCBI Full Gene NameTNF receptor superfamily member 10c
NCBI Gene AliasesCD263, DCR1, DCR1-TNFR, LIT, TRAIL-R3, TRAILR3, TRID
Clonalitymonoclonal
Research AreaFor research use only
Regulatory StatusFor research use only

Add to Compare List

Miltenyi Biotec

Local Office

Miltenyi Biotec

Miltenyi Biotec Inc.

2303 Lindbergh Street

Auburn, CA 95602

United States

Phone: Phone: +1 530 888 8871
Toll Free: 800 FOR MACS
Fax: +1 530 888 8925

Email: macs@miltenyibiotec.com

Company Profile

Website: www.miltenyibiotec.com

International Office

Miltenyi Biotec

Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68

51429 Bergisch Gladbach

Germany

Phone: +49 2204 8306-0
Fax: +49 2204 8306-235

Email: macs@miltenyibiotec.de

Company Profile

Website: www.miltenyibiotec.com

(1) Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor developmentMolecular and cellular biologySeptember 1, 2007Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, et al.

(2) Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAILJournal of immunology (Baltimore, Md. : 1950)January 1, 1998Mongkolsapaya J, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell JI, Screaton GR.

(3) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor familyThe Journal of experimental medicineOctober 6, 1997Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA.

Be the First to Write a Review!